ClinicalTrials.gg
TerminatedNCT04246177Updated Sep 3, 2026Results posted

Safety and Efficacy of Lenvatinib (E7080/MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma (MK-7902-012/E7080-G000-318/LEAP-012)

A Phase 3 interventional study of Lenvatinib and Pembrolizumab in Carcinoma, Hepatocellular, sponsored by Merck Sharp & Dohme LLC. Terminated at 205 sites in 27 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-09-03.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Why this study was terminated
Business Reasons

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
480
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 121 studies testing lenvatinib in Carcinoma, Hepatocellular — 57 open to participants now, 65 under way, 7 of them phase 3. lenvatinib · Carcinoma, Hepatocellular.

Enrollment
4th of 121
480 · median 48
Started
2020
with 12 others
Phase 3
13 of 121
4 open now
Registered
26th of 121
by date

Among the 121 studies testing lenvatinib in Carcinoma, Hepatocellular, this one is the 4th largest by enrollment, is one of 13 that started in 2020, is one of 13 in phase 3, and was the 26th registered.

Carcinoma, Hepatocellular

3,651 studies on the registry are indexed under Carcinoma, Hepatocellular; 1,063 are open to participants now.

Browse Carcinoma, Hepatocellular studies →

Open to participants now

57 of the 121 studies testing lenvatinib in Carcinoma, Hepatocellular are open now, in 6 countries. Recruiting first, the newest first:

52 more — sign in →

By country, each count listing its studies:

All 57 open studies →

About lenvatinib

lenvatinib: first FDA approval 2015 (LENVIMA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 739 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 249 (34%) stop at 75 or younger; 31 take children under 18; 31 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 121 studies testing lenvatinib in Carcinoma, Hepatocellular, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of lenvatinib and pembrolizumab in combination with TACE versus TACE plus oral and intravenous (IV) placebos in participants with incurable, non-metastatic hepatocellular carcinoma (HCC). The primary hypotheses are that pembrolizumab plus lenvatinib in combination with TACE is superior to placebo plus TACE with respect to progression-free survival (PFS) and overall survival (OS).

03

Conditions studied

  • Carcinoma, Hepatocellular

Keywords

  • receptor tyrosine kinase inhibitor
  • programmed cell death 1 (PD-1, PD1)
  • programmed cell death ligand 1 (PD-L1, PDL1)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has a diagnosis of HCC confirmed by radiology, histology, or cytology
  • Has HCC localized to the liver and not amenable to curative treatment
  • Participants with virus (HCV) are eligible if treatment was completed at least 1 month prior to starting study intervention
  • Participants with virus (HBV) are eligible
  • Has adequately controlled blood pressure with or without antihypertensive medications
  • Has adequate organ function

Exclusion criteria

Exclusion Criteria:

  • Is currently a candidate for liver transplantation
  • Has had gastric bleeding within the last 6 months
  • Has ascites that is not controlled with medication
  • Has significant cardiovascular impairment within 12 months of the first dose of study intervention such as congestive heart failure
  • Has a serious nonhealing wound, ulcer, or bone fracture
  • Has received locoregional therapy to existing liver lesions
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
480 participants (actual)

Study arms

  • Experimental
    Lenvatinib plus Pembrolizumab plus TACE

    Participants will receive a combination of lenvatinib, pembrolizumab, and TACE. Lenvatinib will be administered at a dose of 12 mg (for participants with screening body weight ≥60 kg) or 8 mg (for participants with screening body weight \<60 kg) orally once a day during each 21-day cycle until progressive disease or unacceptable toxicity (up to 2 years \[\~35 cycles\] or longer with Sponsor approval). Pembrolizumab will be administered via IV infusion at a dose of 400 mg once every 6 weeks (Q6W) for up to 2 years (\~17 doses). Participants will undergo TACE as a background procedure of chemotherapeutic and embolic agent(s).

    Drug: Lenvatinib · Biological: Pembrolizumab · Procedure: TACE

  • Active comparator
    Oral Placebo plus IV Placebo plus TACE

    Participants will receive a combination of lenvatinib-matching oral placebo, pembrolizumab-matching IV placebo, and TACE. Lenvatinib-matching oral placebo will be administered once a day during each 21-day cycle for up to 2 years (\~35 cycles) or longer with Sponsor approval and pembrolizumab-matching IV placebo will be administered once every 6 weeks (Q6W) for up to 2 years (\~17 doses). Participants will undergo TACE as a background procedure of chemotherapeutic and embolic agent(s).

    Drug: Oral Placebo · Drug: IV Placebo · Procedure: TACE

Interventions

  • Administered at a dose of 12 mg (for participants with screening body weight ≥60 kg) or 8 mg (for participants with screening body weight \<60 kg) via oral capsules once a day during each 21-day cycle.

    Also known as: MK-7902, E7080, LENVIMA®

  • BiologicalPembrolizumab

    Administered via IV infusion at a dose of 400 mg once every 6 weeks (Q6W).

    Also known as: MK-3475, KEYTRUDA®

  • DrugOral Placebo

    Lenvatinib-matching placebo administered via oral capsules once a day during each 21-day cycle.

  • DrugIV Placebo

    Pembrolizumab-matching placebo administered via IV infusion once every 6 weeks (Q6W).

  • ProcedureTACE

    Conducted as a background procedure of chemotherapeutic and embolic agent(s).

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)

    PFS was defined as the time from the first dose of study intervention to the first documented progressive disease (PD) per RECIST 1.1 by BICR or death due to any cause, whichever occurs first. Per RECIST 1.1 adjusted for this study to allow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, PD was defined as at least a 20% increase in the sum of diameters (SOD) of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered PD. PFS per RECIST 1.1 as assessed by BICR was reported.

    Time frame: Up to approximately 43.5 Months

  2. Overall Survival (OS)

    OS was defined as the time from randomization to death due to any cause.

    Time frame: Up to approximately 61.7 Months

Secondary outcomes

  1. PFS Per Modified RECIST (mRECIST) as Assessed by BICR

    PFS was defined as the time from the first dose of study intervention to the first documented PD per mRECIST by BICR or death due to any cause, whichever occurs first. mRECIST for hepatocellular carcinoma (HCC) allows evaluation of treatment effects that are not reflected in simple total size changes of lesions. Per mRECIST, PD was defined as an increase of at least 20% in the SODs of viable target lesions, taking as reference the smallest SODs of viable target lesions recorded since the treatment started. PFS per mRECIST as assessed by BICR was reported.

    Time frame: Up to approximately 61.7 Months

  2. Objective Response Rate (ORR) Per mRECIST as Assessed by BICR

    ORR was defined as the percentage of participants who achieve a confirmed complete response (CR) (disappearance of any intratumoral arterial enhancement in all target lesions) or a partial response (PR) (at least a 30% decrease in the SOD of viable \[contrast enhancement in the arterial phase\] target lesions, taking as reference the baseline SOD of target lesions) per mRECIST as assessed by BICR. mRECIST for HCC allows evaluation of treatment effects that are not reflected in simple total size changes of lesions. The percentage of participants who experienced CR or PR per mRECIST as assessed BICR was presented.

    Time frame: Up to approximately 61.7 Months

  3. Disease Control Rate (DCR) Per mRECIST as Assessed by BICR

    DCR was defined as the percentage of participants who have achieved a confirmed complete response (CR) (disappearance of any intratumoral arterial enhancement in all target lesions) or a partial response (PR) (at least a 30% decrease in the SOD of viable \[contrast enhancement in the arterial phase\] target lesions, taking as reference the baseline SOD of target lesions) per mRECIST as assessed by BICR. mRECIST for HCC allows evaluation of treatment effects that are not reflected in simple total size changes of lesions. PD was defined as at least a 20% increase in the SOD of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered PD. The percentage of participants who achieved CR, PR, or SD after ≥6 weeks per mRECIST assessed by BICR was presented.

    Time frame: Up to approximately 61.7 Months

  4. Duration of Response (DOR) Per mRECIST as Assessed by BICR

    For participants who demonstrated confirmed CR or PR per mRECIST assessed by BICR, DOR was defined as the time from the first documented evidence of a confirmed complete response (CR) (disappearance of any intratumoral arterial enhancement in all target lesions) or a partial response (PR) (at least a 30% decrease in the SOD of viable \[contrast enhancement in the arterial phase\] target lesions, taking as reference the baseline SOD of target lesions) per mRECIST as assessed by BICR. mRECIST for HCC allows evaluation of treatment effects that are not reflected in simple total size changes of lesions. PD was defined as at least a 20% increase in the SOD of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered PD. The DOR as assessed using mRECIST for all participants who experienced a confirmed CR or PR was presented.

    Time frame: Up to approximately 61.7 Months

  5. Time-To-Progression (TTP) Per mRECIST as Assessed by BICR

    TTP was defined as the time from the first dose of study intervention to the first documented PD per mRECIST assessed by BICR. mRECIST for HCC allows evaluation of treatment effects that are not reflected in simple total size changes of lesions. PD was defined as at least a 20% increase in the SOD of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered PD. TTP per mRECIST as assessed by BICR was presented.

    Time frame: Up to approximately 61.7 Months

  6. Number of Participants Who Experienced At Least One Adverse Event (AE)

    An AE will be any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who experienced an AE will be reported.

    Time frame: Up to approximately 71.1 Months

  7. Percentage of Participants Who Experience At Least One Serious Adverse Event (SAE)

    An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An SAE was defined as any untoward medical occurrence that, at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was another important medical event. The number of participants with an SAE was reported.

    Time frame: Up to approximately 71.1 Months

  8. Number of Participants Who Experience At Least One Hepatic Event of Clinical Interest (ECI)

    An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Hepatic events of clinical interest (ECIs) included any of the following events if the event was considered not due to disease progression as judged by the investigator: among participants with Baseline ALT \<2 × ULN: ALT ≥5 × ULN; among participants with Baseline ALT ≥2 × ULN: ALT \>3 × the Baseline level; ALT \>500 U/L regardless of baseline level; total bilirubin \>3.0 mg/dL; hepatic decompensation diagnosed clinically (regardless of laboratory values) including new onset clinically detectable ascites requiring intervention for \>3 days, hepatic encephalopathy, or gastrointestinal bleeding suggestive of portal hypertension. The number of participants with a hepatic AE of clinical interest was reported.

    Time frame: Up to approximately 71.1 Months

  9. Number of Participants Who Discontinue Study Treatment Due to an AE

    An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants that discontinued study treatment due to an AE was reported.

    Time frame: Up to approximately 71.1 Months

  10. ORR Per RECIST 1.1 as Assessed by BICR

    ORR was defined as the percentage of participants who achieve a confirmed Complete Response (CR: disappearance of all target lesions) or a Partial Response (PR: at least a 30% decrease in the sum of diameters \[SOD\] of target lesions) per RECIST 1.1 adjusted for this study to allow a maximum of 10 target lesions in total and 5 per organ, and assessed by BICR. The percentage of participants who experienced CR or PR per RECIST 1.1 as assessed BICR was presented.

    Time frame: Up to approximately 61.7 Months

  11. DCR Per RECIST 1.1 as Assessed by BICR

    DCR was defined as the percentage of participants who have achieved CR (disappearance of all target lesions), PR (at least a 30% decrease in the SOD of target lesions), or stable disease (SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD) after ≥6 weeks (the start of the window for the first scheduled scan) per RECIST 1.1 assessed by BICR. Per RECIST 1.1 adjusted for this study to allow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, PD was defined as at least a 20% increase in the SOD of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered PD. The percentage of participants who achieved CR, PR, or SD after ≥6 weeks per RECIST 1.1 assessed by BICR was presented.

    Time frame: Up to approximately 61.7 Months

  12. DOR Per RECIST 1.1 as Assessed by BICR

    For participants who demonstrated confirmed CR or PR per RECIST 1.1 assessed by BICR, DOR was defined as the time from the first documented evidence of CR (disappearance of all target lesions) or PR (at least a 30% decrease in the SOD of target lesions) until progressive disease (PD) or death due to any cause, whichever occurred first. Per RECIST 1.1 adjusted for this study to allow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, PD was defined as at least a 20% increase in the SOD of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered PD. The DOR as assessed using RECIST 1.1 for all participants who experienced a confirmed CR or PR was presented.

    Time frame: Up to approximately 61.7 Months

  13. TTP Per RECIST 1.1 as Assessed by BICR

    TTP was defined as the time from the first dose of study intervention to the first documented PD per RECIST 1.1 assessed by BICR. Per RECIST 1.1 adjusted for this study to allow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, PD was defined as at least a 20% increase in the SOD of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered PD. TTP per RECIST 1.1 as assessed by BICR was presented.

    Time frame: Up to approximately 61.7 Months

07

Results

Posted Sep 3, 2026

Participant flow

Participant flow — Overall Study
MilestoneLenvatinib Plus Pembrolizumab Plus TACEOral Placebo Plus IV Placebo Plus TACE
Started237243
Treated237241
Participants ongoing105114
Completed00
Not completed237243
Withdrew: Death124122
Withdrew: Randomized by mistake without study treatment01
Withdrew: Withdrawal by subject86
Withdrew: Participants ongoing105114

Outcome measures

PrimaryProgression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)

PFS was defined as the time from the first dose of study intervention to the first documented progressive disease (PD) per RECIST 1.1 by BICR or death due to any cause, whichever occurs first. Per RECIST 1.1 adjusted for this study to allow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, PD was defined as at least a 20% increase in the sum of diameters (SOD) of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered PD. PFS per RECIST 1.1 as assessed by BICR was reported.

Time frame:
Up to approximately 43.5 Months
Reported as:
Median · Months
Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)
MonthsLenvatinib + Pembrolizumab + TACEPlacebo + TACE
Progression Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)14.6 (12.6 to 16.7)10.0 (8.1 to 12.2)
Statistical analysis
  • Lenvatinib + Pembrolizumab + TACE vs Placebo + TACE · Re-randomization test · p = 0.0002 (One-sided re-randomization p-value based on 170,000 re-randomizations and log-rank test stratified by AFP (≤400 vs \>400 ng/mL), ECOG PS (0 vs 1), ALBI Grade (1 vs 2 or 3), tumor burden (≤6 vs \>6 but ≤12 vs \>12), geographic (Asia w/ vs w/o Japan).) · Hazard ratio (hr): 0.66 · 95% CI 0.51 to 0.84Cox regression; Efron's method tie handling, treatment covariate stratified: AFP (≤400 vs \>400 ng/mL), ECOG PS (0 vs 1), ALBI Grade (1 vs 2 or 3), tumor burden (≤6 vs \>6 but ≤12 vs \>12), geographic (Asia w/ vs w/o Japan).
PrimaryOverall Survival (OS)

OS was defined as the time from randomization to death due to any cause.

Time frame:
Up to approximately 61.7 Months
Reported as:
Median · Months
Overall Survival (OS)
MonthsLenvatinib + Pembrolizumab + TACEPlacebo + TACE
Overall Survival (OS)40.4 (34.4 to 47.0)40.8 (35.2 to 45.8)
Statistical analysis
  • Lenvatinib + Pembrolizumab + TACE vs Placebo + TACE · Re-randomization test · p = .4442 (One-sided re-randomization p-value based on 170,000 re-randomizations and log-rank test stratified by AFP (≤400 vs \>400 ng/mL), ECOG PS (0 vs 1), ALBI Grade (1 vs 2 or 3), tumor burden (≤6 vs \>6 but ≤12 vs \>12), geographic (Asia w/ vs w/o Japan).) · Hazard ratio (hr): 0.98 · 95% CI 0.76 to 1.26Cox regression; Efron's method tie handling, treatment covariate stratified: AFP (≤400 vs \>400 ng/mL), ECOG PS (0 vs 1), ALBI Grade (1 vs 2 or 3), tumor burden (≤6 vs \>6 but ≤12 vs \>12), geographic (Asia w/ vs w/o Japan).
SecondaryPFS Per Modified RECIST (mRECIST) as Assessed by BICR

PFS was defined as the time from the first dose of study intervention to the first documented PD per mRECIST by BICR or death due to any cause, whichever occurs first. mRECIST for hepatocellular carcinoma (HCC) allows evaluation of treatment effects that are not reflected in simple total size changes of lesions. Per mRECIST, PD was defined as an increase of at least 20% in the SODs of viable target lesions, taking as reference the smallest SODs of viable target lesions recorded since the treatment started. PFS per mRECIST as assessed by BICR was reported.

Time frame:
Up to approximately 61.7 Months
Reported as:
Median · Months
PFS Per Modified RECIST (mRECIST) as Assessed by BICR
MonthsLenvatinib + Pembrolizumab + TACEPlacebo + TACE
PFS Per Modified RECIST (mRECIST) as Assessed by BICR14.6 (12.5 to 17.6)9.8 (8.1 to 11.1)
Statistical analysis
  • Lenvatinib + Pembrolizumab + TACE vs Placebo + TACE · Log Rank · p = .0001 (One-sided nominal p-value based on log-rank test stratified by AFP (≤400 vs \>400 ng/mL), ECOG PS (0 vs 1), ALBI Grade (1 vs 2 or 3), tumor burden (≤6 vs \>6 but ≤12 vs \>12), geographic (Asia w/ vs w/o Japan).) · Hazard ratio (hr): 0.63 · 95% CI 0.49 to 0.81Cox regression; Efron's method tie handling, treatment covariate stratified: AFP (≤400 vs \>400 ng/mL), ECOG PS (0 vs 1), ALBI Grade (1 vs 2 or 3), tumor burden (≤6 vs \>6 but ≤12 vs \>12), geographic (Asia w/ vs w/o Japan).
SecondaryObjective Response Rate (ORR) Per mRECIST as Assessed by BICR

ORR was defined as the percentage of participants who achieve a confirmed complete response (CR) (disappearance of any intratumoral arterial enhancement in all target lesions) or a partial response (PR) (at least a 30% decrease in the SOD of viable \[contrast enhancement in the arterial phase\] target lesions, taking as reference the baseline SOD of target lesions) per mRECIST as assessed by BICR. mRECIST for HCC allows evaluation of treatment effects that are not reflected in simple total size changes of lesions. The percentage of participants who experienced CR or PR per mRECIST as assessed BICR was presented.

Time frame:
Up to approximately 61.7 Months
Reported as:
Number · Percentage of Participants
Objective Response Rate (ORR) Per mRECIST as Assessed by BICR
Percentage of ParticipantsLenvatinib + Pembrolizumab + TACEPlacebo + TACE
Objective Response Rate (ORR) Per mRECIST as Assessed by BICR71.3 (65.1 to 77.0)49.4 (42.9 to 55.8)
Statistical analysis
  • Lenvatinib + Pembrolizumab + TACE vs Placebo + TACE · Log Rank · p = <0.0001 (One-sided nominal p-value for testing. H0: difference in percent equals 0 versus H1: difference in percent greater than 0.) · Difference in percentage: 21.5 · 95% CI 12.7 to 30.0Miettinen \& Nurminen; method stratified by: AFP (≤400 vs \>400 ng/mL), ECOG PS (0 vs 1), ALBI Grade (1 vs 2 or 3), tumor burden (≤6 vs \>6 but ≤12 vs \>12) and geographic (Asia w/ vs w/o Japan).
SecondaryDisease Control Rate (DCR) Per mRECIST as Assessed by BICR

DCR was defined as the percentage of participants who have achieved a confirmed complete response (CR) (disappearance of any intratumoral arterial enhancement in all target lesions) or a partial response (PR) (at least a 30% decrease in the SOD of viable \[contrast enhancement in the arterial phase\] target lesions, taking as reference the baseline SOD of target lesions) per mRECIST as assessed by BICR. mRECIST for HCC allows evaluation of treatment effects that are not reflected in simple total size changes of lesions. PD was defined as at least a 20% increase in the SOD of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered PD. The percentage of participants who achieved CR, PR, or SD after ≥6 weeks per mRECIST assessed by BICR was presented.

Time frame:
Up to approximately 61.7 Months
Reported as:
Number · Percentage of Participants
Disease Control Rate (DCR) Per mRECIST as Assessed by BICR
Percentage of ParticipantsLenvatinib + Pembrolizumab + TACEPlacebo + TACE
Disease Control Rate (DCR) Per mRECIST as Assessed by BICR90.3 (85.8 to 93.7)81.9 (76.5 to 86.5)
SecondaryDuration of Response (DOR) Per mRECIST as Assessed by BICR

For participants who demonstrated confirmed CR or PR per mRECIST assessed by BICR, DOR was defined as the time from the first documented evidence of a confirmed complete response (CR) (disappearance of any intratumoral arterial enhancement in all target lesions) or a partial response (PR) (at least a 30% decrease in the SOD of viable \[contrast enhancement in the arterial phase\] target lesions, taking as reference the baseline SOD of target lesions) per mRECIST as assessed by BICR. mRECIST for HCC allows evaluation of treatment effects that are not reflected in simple total size changes of lesions. PD was defined as at least a 20% increase in the SOD of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered PD. The DOR as assessed using mRECIST for all participants who experienced a confirmed CR or PR was presented.

Time frame:
Up to approximately 61.7 Months
Reported as:
Median · Months
Duration of Response (DOR) Per mRECIST as Assessed by BICR
MonthsLenvatinib + Pembrolizumab + TACEPlacebo + TACE
Duration of Response (DOR) Per mRECIST as Assessed by BICR14.5 (12.5 to 16.6)12.5 (10.4 to 14.7)
SecondaryTime-To-Progression (TTP) Per mRECIST as Assessed by BICR

TTP was defined as the time from the first dose of study intervention to the first documented PD per mRECIST assessed by BICR. mRECIST for HCC allows evaluation of treatment effects that are not reflected in simple total size changes of lesions. PD was defined as at least a 20% increase in the SOD of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered PD. TTP per mRECIST as assessed by BICR was presented.

Time frame:
Up to approximately 61.7 Months
Reported as:
Median · Months
Time-To-Progression (TTP) Per mRECIST as Assessed by BICR
MonthsLenvatinib + Pembrolizumab + TACEPlacebo + TACE
Time-To-Progression (TTP) Per mRECIST as Assessed by BICR16.6 (14.5 to 18.9)10.2 (8.2 to 12.3)
Statistical analysis
  • Lenvatinib + Pembrolizumab + TACE vs Placebo + TACE · Log Rank · p = <0.0001 (One-sided nominal p-value based on log-rank test stratified by AFP (≤400 vs \>400 ng/mL), ECOG PS (0 vs 1), ALBI Grade (1 vs 2 or 3), tumor burden (≤6 vs \>6 but ≤12 vs \>12), geographic (Asia w/ vs w/o Japan).) · Hazard ratio (hr): 0.56 · 95% CI 0.43 to 0.73Cox regression; Efron's method tie handling, treatment covariate stratified: AFP (≤400 vs \>400 ng/mL), ECOG PS (0 vs 1), ALBI Grade (1 vs 2 or 3), tumor burden (≤6 vs \>6 but ≤12 vs \>12), geographic (Asia w/ vs w/o Japan).
SecondaryNumber of Participants Who Experienced At Least One Adverse Event (AE)

An AE will be any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who experienced an AE will be reported.

Time frame:
Up to approximately 71.1 Months

Results for this outcome have not been posted.

SecondaryPercentage of Participants Who Experience At Least One Serious Adverse Event (SAE)

An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. An SAE was defined as any untoward medical occurrence that, at any dose: resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, or was another important medical event. The number of participants with an SAE was reported.

Time frame:
Up to approximately 71.1 Months

Results for this outcome have not been posted.

SecondaryNumber of Participants Who Experience At Least One Hepatic Event of Clinical Interest (ECI)

An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. Hepatic events of clinical interest (ECIs) included any of the following events if the event was considered not due to disease progression as judged by the investigator: among participants with Baseline ALT \<2 × ULN: ALT ≥5 × ULN; among participants with Baseline ALT ≥2 × ULN: ALT \>3 × the Baseline level; ALT \>500 U/L regardless of baseline level; total bilirubin \>3.0 mg/dL; hepatic decompensation diagnosed clinically (regardless of laboratory values) including new onset clinically detectable ascites requiring intervention for \>3 days, hepatic encephalopathy, or gastrointestinal bleeding suggestive of portal hypertension. The number of participants with a hepatic AE of clinical interest was reported.

Time frame:
Up to approximately 71.1 Months

Results for this outcome have not been posted.

SecondaryNumber of Participants Who Discontinue Study Treatment Due to an AE

An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. The number of participants that discontinued study treatment due to an AE was reported.

Time frame:
Up to approximately 71.1 Months

Results for this outcome have not been posted.

SecondaryORR Per RECIST 1.1 as Assessed by BICR

ORR was defined as the percentage of participants who achieve a confirmed Complete Response (CR: disappearance of all target lesions) or a Partial Response (PR: at least a 30% decrease in the sum of diameters \[SOD\] of target lesions) per RECIST 1.1 adjusted for this study to allow a maximum of 10 target lesions in total and 5 per organ, and assessed by BICR. The percentage of participants who experienced CR or PR per RECIST 1.1 as assessed BICR was presented.

Time frame:
Up to approximately 61.7 Months
Reported as:
Number · Percentage of Participants
ORR Per RECIST 1.1 as Assessed by BICR
Percentage of ParticipantsLenvatinib + Pembrolizumab + TACEPlacebo + TACE
ORR Per RECIST 1.1 as Assessed by BICR48.1 (41.6 to 54.7)33.7 (27.8 to 40.1)
Statistical analysis
  • Lenvatinib + Pembrolizumab + TACE vs Placebo + TACE · Log Rank · p = 0.0005 (One-sided nominal p-value for testing. H0: difference in percent equals 0 versus H1: difference in percent greater than 0.) · Difference in percentage: 14.9 · 95% CI 6.1 to 23.4Miettinen \& Nurminen; method stratified by: AFP (≤400 vs \>400 ng/mL), ECOG PS (0 vs 1), ALBI Grade (1 vs 2 or 3), tumor burden (≤6 vs \>6 but ≤12 vs \>12) and geographic (Asia w/ vs w/o Japan).
SecondaryDCR Per RECIST 1.1 as Assessed by BICR

DCR was defined as the percentage of participants who have achieved CR (disappearance of all target lesions), PR (at least a 30% decrease in the SOD of target lesions), or stable disease (SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD) after ≥6 weeks (the start of the window for the first scheduled scan) per RECIST 1.1 assessed by BICR. Per RECIST 1.1 adjusted for this study to allow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, PD was defined as at least a 20% increase in the SOD of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered PD. The percentage of participants who achieved CR, PR, or SD after ≥6 weeks per RECIST 1.1 assessed by BICR was presented.

Time frame:
Up to approximately 61.7 Months
Reported as:
Number · Percentage of participants
DCR Per RECIST 1.1 as Assessed by BICR
Percentage of participantsLenvatinib + Pembrolizumab + TACEPlacebo + TACE
DCR Per RECIST 1.1 as Assessed by BICR89.9 (85.3 to 93.4)81.1 (75.6 to 85.8)
SecondaryDOR Per RECIST 1.1 as Assessed by BICR

For participants who demonstrated confirmed CR or PR per RECIST 1.1 assessed by BICR, DOR was defined as the time from the first documented evidence of CR (disappearance of all target lesions) or PR (at least a 30% decrease in the SOD of target lesions) until progressive disease (PD) or death due to any cause, whichever occurred first. Per RECIST 1.1 adjusted for this study to allow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, PD was defined as at least a 20% increase in the SOD of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered PD. The DOR as assessed using RECIST 1.1 for all participants who experienced a confirmed CR or PR was presented.

Time frame:
Up to approximately 61.7 Months
Reported as:
Median · Months
DOR Per RECIST 1.1 as Assessed by BICR
MonthsLenvatinib + Pembrolizumab + TACEPlacebo + TACE
DOR Per RECIST 1.1 as Assessed by BICR14.3 (12.1 to 16.6)12.6 (9.8 to 16.9)
SecondaryTTP Per RECIST 1.1 as Assessed by BICR

TTP was defined as the time from the first dose of study intervention to the first documented PD per RECIST 1.1 assessed by BICR. Per RECIST 1.1 adjusted for this study to allow a maximum of 10 target lesions and a maximum of 5 target lesions per organ, PD was defined as at least a 20% increase in the SOD of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions was also considered PD. TTP per RECIST 1.1 as assessed by BICR was presented.

Time frame:
Up to approximately 61.7 Months
Reported as:
Median · Months
TTP Per RECIST 1.1 as Assessed by BICR
MonthsLenvatinib + Pembrolizumab + TACEPlacebo + TACE
TTP Per RECIST 1.1 as Assessed by BICR16.6 (14.6 to 18.5)10.4 (8.2 to 12.5)
Statistical analysis
  • Lenvatinib + Pembrolizumab + TACE vs Placebo + TACE · Log Rank · p = 0.0002 (One-sided nominal p-value based on log-rank test stratified by AFP (≤400 vs \>400 ng/mL), ECOG PS (0 vs 1), ALBI Grade (1 vs 2 or 3), tumor burden (≤6 vs \>6 but ≤12 vs \>12), geographic (Asia w/ vs w/o Japan).) · Hazard ratio (hr): 0.64 · 95% CI 0.50 to 0.82Cox regression; Efron's method tie handling, treatment covariate stratified: AFP (≤400 vs \>400 ng/mL), ECOG PS (0 vs 1), ALBI Grade (1 vs 2 or 3), tumor burden (≤6 vs \>6 but ≤12 vs \>12), geographic (Asia w/ vs w/o Japan).

Adverse events

Collected over Up to approximately 61.7 Months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Lenvatinib + Pembrolizumab + TACE126/237 (53.2%)122/237 (51.5%)234/237 (98.7%)
Placebo + TACE127/243 (52.3%)62/241 (25.7%)229/241 (95%)
Most frequent serious events
Showing 10 of 176
Most frequent serious events
EventLenvatinib + Pembrolizumab + TACEPlacebo + TACE
Hepatic encephalopathyNervous system disorders12/2372/241
DiarrhoeaGastrointestinal disorders8/2370/241
Blood bilirubin increasedInvestigations8/2370/241
AscitesGastrointestinal disorders7/2370/241
Liver abscessInfections and infestations3/2376/241
Oesophageal varices haemorrhageGastrointestinal disorders5/2373/241
Platelet count decreasedInvestigations3/2375/241
Acute myocardial infarctionCardiac disorders4/2370/241
Gastrointestinal haemorrhageGastrointestinal disorders4/2371/241
Cholecystitis acuteHepatobiliary disorders4/2370/241
Most frequent other events
Showing 10 of 64
Most frequent other events
EventLenvatinib + Pembrolizumab + TACEPlacebo + TACE
HypertensionVascular disorders126/23753/241
ProteinuriaRenal and urinary disorders105/23727/241
Platelet count decreasedInvestigations96/23763/241
Alanine aminotransferase increasedInvestigations94/23779/241
Aspartate aminotransferase increasedInvestigations92/23777/241
Weight decreasedInvestigations91/23717/241
HypothyroidismEndocrine disorders84/23720/241
Blood bilirubin increasedInvestigations84/23756/241
Decreased appetiteMetabolism and nutrition disorders83/23731/241
DiarrhoeaGastrointestinal disorders76/23722/241

Baseline characteristics

The baseline analysis population consisted of all randomized participants. Participants will be analyzed in the treatment group to which they are randomized.

Age, Continuous
Age, Continuous(Years)Lenvatinib + Pembrolizumab + TACEPlacebo + TACETotal
Mean63.8 ± 10.765.2 ± 10.464.5 ± 10.6
Sex: Female, Male
Sex: Female, Male(Participants)Lenvatinib + Pembrolizumab + TACEPlacebo + TACETotal
Female453782
Male192206398
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Lenvatinib + Pembrolizumab + TACEPlacebo + TACETotal
Hispanic or Latino313364
Not Hispanic or Latino193199392
Unknown or Not Reported131124
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Lenvatinib + Pembrolizumab + TACEPlacebo + TACETotal
American Indian or Alaska Native325
Asian168179347
Native Hawaiian or Other Pacific Islander000
Black or African American224
White514798
More than one race7714
Unknown or Not Reported6612
Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) at Baseline
Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) at Baseline(Participants)Lenvatinib + Pembrolizumab + TACEPlacebo + TACETotal
ECOG= 0216213429
ECOG= 1213051
Geographic Region
Geographic Region(Participants)Lenvatinib + Pembrolizumab + TACEPlacebo + TACETotal
Asia without Japan135137272
Non-Asia with Japan102106208
Serum Albumin (ALBI) Grade
Serum Albumin (ALBI) Grade(Participants)Lenvatinib + Pembrolizumab + TACEPlacebo + TACETotal
Grade 1171174345
Grade 26569134
Missing101
Tumor Burden Stratum per Investigator
Tumor Burden Stratum per Investigator(Participants)Lenvatinib + Pembrolizumab + TACEPlacebo + TACETotal
≤ 6112116228
> 6 and ≤ 12120117237
> 1251015

1 further baseline measures are reported on the registry.

08

Study locations

205 sites
  • Arizona Oncology Associates PC- HOPE ( Site 0770)
    Tucson, Arizona 85711, United States
  • Scripps Clinic Torrey Pines ( Site 0714)
    La Jolla, California 92037, United States
  • USC Norris Comprehensive Cancer Center ( Site 0717)
    Los Angeles, California 90033, United States
  • UCLA Hematology/Oncology - Santa Monica ( Site 0720)
    Los Angeles, California 90404, United States
  • UC Irvine Health ( Site 0718)
    Orange, California 92868, United States
  • Yale Cancer Center ( Site 0724)
    New Haven, Connecticut 06510, United States
  • Tampa General Hospital ( Site 0764)
    Tampa, Florida 33606, United States
  • Mountain States Tumor Institute ( Site 0773)
    Boise, Idaho 83712, United States
  • University of Iowa Hospital and Clinics ( Site 0729)
    Iowa City, Iowa 52242, United States
  • University of Kansas Cancer Center ( Site 0731)
    Westwood, Kansas 66205, United States
  • University of Louisville ( Site 0757)
    Louisville, Kentucky 40202, United States
  • Tulane Medical Center ( Site 0787)
    New Orleans, Louisiana 70112, United States
  • University Medical Center New Orleans ( Site 0733)
    New Orleans, Louisiana 70112, United States
  • Henry Ford Hospital-GI/Hepatology Research ( Site 0735)
    Detroit, Michigan 48202, United States
  • Saint Louis University ( Site 0769)
    St Louis, Missouri 63110, United States
  • University of New Mexico Comprehensive Cancer Center ( Site 0805)
    Albuquerque, New Mexico 87106, United States
  • Monter Cancer Center ( Site 0780)
    Lake Success, New York 11042, United States
  • Icahn School of Medicine at Mount Sinai ( Site 0744)
    New York, New York 10029, United States
  • Wake Forest Baptist Health ( Site 0741)
    Winston-Salem, North Carolina 27157, United States
  • University of Cincinnati Medical Center ( Site 0791)
    Cincinnati, Ohio 45219, United States
  • The Ohio State University Wexner Medical Center ( Site 0759)
    Columbus, Ohio 43210, United States
  • ProMedica Flower Hospital ( Site 0796)
    Sylvania, Ohio 43560, United States
  • Stephenson Cancer Center ( Site 0745)
    Oklahoma City, Oklahoma 73104, United States
  • OHSU Center for Health & Healing ( Site 0746)
    Portland, Oregon 97239, United States
  • Penn State Hershey Medical Center ( Site 0766)
    Hershey, Pennsylvania 17033-0850, United States
  • Houston Methodist Research Institute ( Site 0784)
    Houston, Texas 77030, United States
  • Edwards Comprehensive Cancer Center ( Site 0786)
    Huntington, West Virginia 25701, United States
  • St George Hospital ( Site 0005)
    Kogarah, New South Wales 2217, Australia
  • Westmead Hospital-Gastroenterology & Hepatology ( Site 0009)
    Westmead, New South Wales 2145, Australia
  • Princess Alexandra Hospital ( Site 0006)
    Brisbane, Queensland 4102, Australia
  • Austin Health ( Site 0008)
    Heidelberg, Victoria 3084, Australia
  • Alfred Health ( Site 0004)
    Melbourne, Victoria 3004, Australia
  • Royal Perth Hospital ( Site 0002)
    Perth, Western Australia 6000, Australia
  • Liga Norte Riograndense Contra o Câncer-Centro de Pesquisa Clínica ( Site 0057)
    Natal, Rio Grande do Norte 59075-740, Brazil
  • Hospital Nossa Senhora da Conceição-Centro Integrado de Pesquisa em Oncologia ( Site 0056)
    Porto Alegre, Rio Grande do Sul 91350-200, Brazil
  • Clinica de Oncologia Reichow ( Site 0052)
    Blumenau, Santa Catarina 89010-340, Brazil
  • Fundação Pio XII - Hospital de Câncer de Barretos-Unidade de Pesquisa Clínica ( Site 0058)
    Barretos, São Paulo 14784-400, Brazil
  • Fundacao Dr Amaral Carvalho ( Site 0050)
    Jaú, São Paulo 17210-120, Brazil
  • Hospital de Base de Sao Jose de Rio Preto ( Site 0043)
    São José do Rio Preto, São Paulo 15090-000, Brazil
  • BP - A Beneficencia Portuguesa de São Paulo ( Site 0046)
    São Paulo, São Paulo 01323-001, Brazil
  • A.C. Camargo Cancer Center ( Site 0054)
    São Paulo, 01509-900, Brazil
  • Centro Investigación del Cáncer James Lind ( Site 0064)
    Temuco, Araucania 4800827, Chile
  • Centro de Oncología de Precisión-Oncology ( Site 0068)
    Santiago, Region M. de Santiago 7560908, Chile
  • Centro de Cancer Nuestra Senora de la Esperanza ( Site 0065)
    Santiago, Region M. de Santiago 8330024, Chile
  • Bradfordhill ( Site 0066)
    Santiago, Region M. de Santiago 8420383, Chile
  • Anhui Provincial Hospital ( Site 0092)
    Heifei, Anhui 230001, China
  • Beijing Cancer Hospital ( Site 0099)
    Beijing, Beijing Municipality 100142, China
  • Beijing Cancer Hospital ( Site 0105)
    Beijing, Beijing Municipality 100142, China
  • Peking Union Medical College Hospital ( Site 0087)
    Beijing, Beijing Municipality 100730, China
  • Chinese People s Liberation Army Army Characteristic Medical Center ( Site 0117)
    Chongqing, Chongqing Municipality 400042, China
  • Chongqing University Three Gorges Hospital ( Site 0859)
    Chongqing, Chongqing Municipality 404000, China
  • Mengchao Hepatobiliary Hospital of Fujian Medical University ( Site 0121)
    Fuzhou, Fujian 350008, China
  • Fujian Provincial Cancer Hospital ( Site 0085)
    Fuzhou, Fujian 350014, China
  • The First Affiliated Hospital of Fujian Medical University ( Site 0089)
    Fuzhou, Fujian 350014, China
  • Zhongshan Hospital Fudan University (Xiamen Branch) ( Site 0133)
    Xiamen, Fujian 361015, China
  • Zhujiang Hospital of Southern Medical University ( Site 0115)
    Guangzhou, Guangdong 510000, China
  • Guangdong Provincial People s Hospital ( Site 0100)
    Guangzhou, Guangdong 510080, China
  • NANFANG HOSPITAL SOUTHERN MEDICAL UNIVERSITY ( Site 0088)
    Guangzhou, Guangdong 510515, China
  • SUN YAT-SEN UNIVERSITY CANCER CENTRE ( Site 0128)
    Guangzhou, Guangdong 510700, China
  • Jinan University - Zhuhai People's Hospital-Intervention Department ( Site 0856)
    Zhuhai, Guangdong 519000, China
  • Guangxi Medical University Affiliated Tumor Hospital-Hepatological surgery ( Site 0862)
    Nanning, Guangxi 530021, China
  • Hainan General Hospital ( Site 0112)
    Haikou, Hainan 570311, China
  • Harbin Medical University Cancer Hospital ( Site 0090)
    Harbin, Heilongjiang 150081, China
  • Henan Cancer Hospital ( Site 0114)
    Zhengzhou, Henan 450008, China
  • Tongji Hospital Tongji Medical,Science & Technology ( Site 0126)
    Wuhan, Hubei 430000, China
  • Hubei Cancer Hospital ( Site 0101)
    Wuhan, Hubei 430079, China
  • Hunan Provincial People's Hospital ( Site 0113)
    Changsha, Hunan 410005, China
  • Hunan Cancer Hospital ( Site 0096)
    Changsha, Hunan 410013, China
  • The First Affiliated Hospital of Soochow University ( Site 0120)
    Suzhou, Jiangsu 215006, China
  • Jiangxi Provincial Cancer Hospital-Cancer Hospital ( Site 0134)
    Nanchang, Jiangxi 330029, China
  • Xi'an International Medical Center Hospital ( Site 0860)
    Xi'an, Shaanxi 710100, China
  • The Third Affiliated Hospital of the PLA Navy Medical University ( Site 0123)
    Shanghai, Shanghai Municipality 200028, China
  • Fudan University Shanghai Cancer Center ( Site 0106)
    Shanghai, Shanghai Municipality 200032, China
  • Zhongshan Hospital Fudan University ( Site 0084)
    Shanghai, Shanghai Municipality 200032, China
  • The First Affiliated Hospital of Xi an Jiaotong University ( Site 0108)
    Xi’an, Shanxi 710048, China
  • West China Hospital of Sichuan University ( Site 0119)
    Chengdu, Sichuan 610041, China
  • Suining Central Hospital ( Site 0857)
    Suining, Sichuan 629000, China
  • Tianjin Medical University Cancer Institute & Hospital ( Site 0098)
    Tianjin, Tianjin Municipality 300060, China
  • Tianjin Third Central Hospital ( Site 0861)
    Tianjin, Tianjin Municipality 300170, China
  • The First Hospital of Kunming ( Site 0124)
    Kunming, Yunnan 650200, China
  • 2nd Affil Hosp of Zhejiang University College of Medicine ( Site 0110)
    Hangzhou, Zhejiang 310009, China
  • Sir Run Run Shaw Hospital ( Site 0094)
    Hangzhou, Zhejiang 310018, China
  • Zhejiang Cancer Hospital ( Site 0103)
    Hangzhou, Zhejiang 310022, China
  • Ningbo Medical Center LiHuili Hospital ( Site 0132)
    Ningbo, Zhejiang 315048, China
  • Hospital Pablo Tobon Uribe ( Site 0145)
    Medellín, Antioquia 050034, Colombia
  • Administradora Country S.A. ( Site 0137)
    Bogotá, Bogota D.C. 110221, Colombia
  • Fundacion Cardiovascular de Colombia ( Site 0136)
    Piedecuesta, Santander Department 681017, Colombia
  • Fundación Valle del Lili ( Site 0140)
    Cali, Valle del Cauca Department 760032, Colombia
  • Herlev Hospital ( Site 0170)
    Herlev, Capital Region 2730, Denmark
  • Aarhus Universitets hospital ( Site 0175)
    Aarhus N, Central Jutland 8200, Denmark
  • Odense Universitetshospital ( Site 0160)
    Odense, Region Syddanmark 5000, Denmark
  • Hopital de la Croix-Rousse ( Site 0193)
    Lyon, Auvergne 69004, France
  • Hopital de la Timone ( Site 0188)
    Marseille, Bouches-du-Rhone 13005, France
  • CHU Bordeaux Haut-Leveque ( Site 0185)
    Pessac, Gironde 33604, France
  • C.H.U. de Nancy. Hopital de Brabois Adultes ( Site 0180)
    Vandœuvre-lès-Nancy, Meurthe-et-Moselle 54500, France
  • A.P.H. Paris, Hopital Henri Mondor ( Site 0179)
    Créteil, Val-de-Marne 94000, France
  • Hopital Paul Brousse ( Site 0182)
    Villejuif, Val-de-Marne 94800, France
  • Universitaetsklinikum Freiburg ( Site 0199)
    Freiburg im Breisgau, Baden-Wurttemberg 79106, Germany
  • Krankenhaus Nord-West GmbH ( Site 0208)
    Frankfurt am Main, Hesse 60488, Germany
  • Medizinische Hochschule Hannover ( Site 0200)
    Hanover, Lower Saxony 30625, Germany

Showing the first 100 of 205 sites across 27 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Kudo M, Ren Z, Guo Y, Han G, Lin H, Zheng J, Ogasawara S, Kim JH, Zhao H, Li C, Madoff DC, Ghobrial RM, Kawaoka T, Gerolami R, Ikeda M, Kumada H, El-Khoueiry AB, Vogel A, Peng X, Mody K, Dutcus C, Dubrovsky L, Siegel AB, Finn RS, Llovet JM; LEAP-012 investigators. Transarterial chemoembolisation combined with lenvatinib plus pembrolizumab versus dual placebo for unresectable, non-metastatic hepatocellular carcinoma (LEAP-012): a multicentre, randomised, double-blind, phase 3 study. Lancet. 2025 Jan 18;405(10474):203-215. doi: 10.1016/S0140-6736(24)02575-3. Epub 2025 Jan 8. PubMed 39798578 ↗
  • Verset G, Borbath I, Karwal M, Verslype C, Van Vlierberghe H, Kardosh A, Zagonel V, Stal P, Sarker D, Palmer DH, Vogel A, Edeline J, Cattan S, Kudo M, Cheng AL, Ogasawara S, Daniele B, Chan SL, Knox JJ, Qin S, Siegel AB, Chisamore M, Hatogai K, Wang A, Finn RS, Zhu AX. Pembrolizumab Monotherapy for Previously Untreated Advanced Hepatocellular Carcinoma: Data from the Open-Label, Phase II KEYNOTE-224 Trial. Clin Cancer Res. 2022 Jun 13;28(12):2547-2554. doi: 10.1158/1078-0432.CCR-21-3807. PubMed 35421228 ↗
  • Llovet JM, Vogel A, Madoff DC, Finn RS, Ogasawara S, Ren Z, Mody K, Li JJ, Siegel AB, Dubrovsky L, Kudo M. Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment. Cardiovasc Intervent Radiol. 2022 Apr;45(4):405-412. doi: 10.1007/s00270-021-03031-9. Epub 2022 Feb 4. PubMed 35119481 ↗
  • Taylor MH, Schmidt EV, Dutcus C, Pinheiro EM, Funahashi Y, Lubiniecki G, Rasco D. The LEAP program: lenvatinib plus pembrolizumab for the treatment of advanced solid tumors. Future Oncol. 2021 Feb;17(6):637-648. doi: 10.2217/fon-2020-0937. Epub 2020 Dec 10. PubMed 33300372 ↗
  • Kloeckner R, Galle PR, Bruix J. Local and Regional Therapies for Hepatocellular Carcinoma. Hepatology. 2021 Jan;73 Suppl 1:137-149. doi: 10.1002/hep.31424. Epub 2020 Nov 6. No abstract available. PubMed 32557715 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2020 to primary completion in Aug 2025, 62 months.

Results were first posted in Sep 2026, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2020
First posted
Jan 29, 2020
StartActual
May 22, 2020
Primary completionActual
Aug 19, 2025
CompletionActual
Mar 26, 2026
Results first posted
Sep 3, 2026
Last update
Sep 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04246177
Collaborators
Eisai Inc.
Responsible party
Sponsor
First posted
Jan 29, 2020
Start date
May 22, 2020
Primary completion
Aug 19, 2025
Completion
Mar 26, 2026
Results posted
Sep 3, 2026
Last update
Sep 3, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lenvatinib · Pembrolizumab

Start the discussion